Plasma levels of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in chronic heart failure - predictors and prognostic relevance.

Abstract

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane protein expressed on myeloid cells, including macrophages and microglia, and is involved in modulating inflammation and lipid metabolism. Elevated plasma levels of soluble TREM2 (sTREM2) have been associated with heart failure (HF) and neurodegenerative diseases such as Alzheimer's disease (AD). This post-hoc analysis explored the association of plasma sTREM2 with cognition and mortality in the Cognition.Matters-HF cohort of 148 chronic HF patients. Plasma sTREM2 levels were measured using a bead-based immunoassay, and the cohort was split into high and low sTREM2 groups based on a median concentration of 16.6 ng/ml. Higher sTREM2 levels were associated with worse cognitive performance, particularly in working memory (T = -2.67, p = 0.009) and visual/verbal memory (T = -2.16, p = 0.032), but not with cardiac function. In univariate cox regression, a higher plasma sTREM2 concentration was linked to increased mortality (HR = 1.28, 95% CI 1.05-1.57, p = 0.015), although this association did not remain significant after adjusting for age and heart failure severity (adjusted HR = 0.95, 95% CI 0.70-1.28, p = 0.720). These findings suggest that plasma sTREM2 reflects cognitive impairment more than cardiac dysfunction in HF, highlighting its potential as a biomarker for neuroinflammation in HF patients.